Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Innovative Molecules GmbH has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 examiner and 1 art unit. ROMERO, KRISTEN WANG is the busiest examiner, with 1 pending matter. The profile reflects a single examination path.
Counsel can focus on the examiner’s treatment of the claimed molecule, biological activity, pharmaceutical use, or related subject matter. Any amendment should identify a concrete technical distinction and connect it to written-description support, rather than relying only on a stated purpose. The single examiner and art-unit assignment simplify prosecution coordination. A focused response or interview can be planned around the specific objections and can preserve a clear record for later claim-scope decisions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729411 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18729411 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND PROCESS OF PREPARATION THEREOF | ROMERO, KRISTEN WANG | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Jul 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovative Molecules GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kristen Wang Romero has the most, with 1 of Innovative Molecules GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
